Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

Inclusion Criteria: * Age 18-75 years old, regardless of gender and race; * Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPEC treatment; * KPS score ≥ 60, with expected survival time more than 12 months; * The functions of important organs are basically normal, with no significant abnormalities in liver or kidney function; * No history of allergy to biological products; * No serious bacterial or viral infection; * Non-pregnancy and lactation; * The patient or his/her delegate understands and cooperates with the treatment and signs the informed consent for the treatment. Exclusion Criteria: * Highly allergic or with a history of severe allergies, especially to biological products; * Shock, systemic failure, unstable vital signs, and inability to cooperate with the examination; * Those who have mental or psychological diseases and cannot cooperate with treatment and curative effect evaluation; * T-lymphocyte carcinoma/tumor; * Patients with systemic infection or severe local infection requiring anti-infection treatment; * Complicated with dysfunction of heart, lung, brain, kidney, liver and other important organs; * Coagulation disorders (e.g., hemophilia); * Infectious diseases (e.g. HIV, RPR, active TB, etc.); * Pregnant or lactating women, or women who have pregnancy plans within half a year; * Patients who are taking immunosuppressive drugs or long-term anti-rejection drugs after organ transplantation; * Patients with severe autoimmune diseases…